SecBot SecBot
6-K ·Filed Jun 23, 2026

ARGX

ARGENX SE
NEUTRAL
Impact 4/10
Horizonweeks Processed4mo ago SEC0001104659-26-076606
Notable filing: 6-K
Actionable Insight • Neutral

Monitor the webinar replay and any published slides for clinical development updates in autoimmune myositis, a new indication for FcRn blockers. The cross-filing context suggests this announcement may carry more weight than a standalone webinar; watch for subsequent filings (e.g., clinical data releases, regulatory updates) that could build on this narrative.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$853.40
T+0 close · Jun 23, 2026 · via day close
Latest settled
+15.38%
T+60 · $984.69
Vs SPY
+12.14%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 23 $853.40entry
  2. T+1 · 5mo ago −0.11%α −0.06% · $852.50
  3. T+5 · 5mo ago +6.92%α +5.91% · $912.46
  4. T+20 · 4mo ago −0.84%α −2.00% · $846.19
  5. T+60 · 2mo ago +15.38%α +12.14% · $984.69
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Argenx announced a webinar on advancing FcRn leadership into autoimmune myositis, featuring key opinion leaders. While the filing is informational and lacks concrete data, the cross-filing context of a 20-F annual report creates an amplifying event that frames this as part of a broader pipeline narrative, supporting a neutral-to-positive read.

Key Facts

  • Webinar titled 'R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis' scheduled for June 23, 2026 at 2:00pm ET.
  • External participants include key opinion leaders from Harvard Medical School, Northwestern University, and University of Pittsburgh.
  • Cross-filing context includes a 20-F annual report filed 96 days prior, with statistically significant amplifier verdicts for 6K-activist-context + 6K-annual-context combinations.

Financial Impact

No financial figures disclosed; webinar is pipeline-focused and not a data release or regulatory milestone.

pipeline_progressinvestor_sentiment

Risk Factors

  • R&D webinars are routine pipeline communication with no guaranteed impact on stock price.
  • Autoimmune myositis is an early-stage indication for argenx; no clinical data or regulatory milestone was announced.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
92% bullish (25 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001104659-26-076606
Document: tm2618529d1_ex99-1.htm0001104659-26-076606
Document: 0001104659-26-076606-index-headers.html0001104659-26-076606
Document: 0001104659-26-076606-index.html0001104659-26-076606
Document: 0001104659-26-076606.txt0001104659-26-076606

Track record

23 reports on ARGX

Performance horizon

7 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +30.22% at T+60 after the Jun 3, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 9, 20267d ago 6-K Bullish 6/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
  2. Nov 9, 20267d ago 6-K Neutral 5/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
  3. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
  4. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $894.77 Now $950.95 +6.28% settles Dec 4
  5. Oct 29, 202618d ago Institutional Cluster Neutral 3/10 Entry $897.85 Now $950.95 +5.91% settles Nov 27
  6. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $875.76 Now $950.95 +8.59% settles Nov 19
  7. Oct 19, 202628d ago 6-K Bullish 7/10 Entry $825.61 to $950.95 Now $950.95 +15.18% ▲ +15.18% +18.64% vs SPY
  8. Oct 8, 20265w ago 6-K Mixed 6/10 Entry $818.63 to $931.38 Now $950.95 +16.16% ▲ +13.77% +19.06% vs SPY
  9. Sep 29, 20266w ago 6-K Bullish 6/10 Entry $970.66 to $871.52 Now $950.95 −2.03% ▼ −10.21% −10.87% vs SPY
  10. Sep 10, 20269w ago Institutional Cluster Mixed 5/10 Entry $984.04 to $818.63 Now $950.95 −3.36% ▼ −16.81% −18.93% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (11h 38m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 23, 2026